Scarica l'app Stockscreener
2.99
6.41%
0.18
Dopo l'orario di chiusura:
3.05
0.06
+2.01%
Precedente Chiudi:
$2.81
Aprire:
$2.77
Volume 24 ore:
920.55K
Relative Volume:
1.98
Capitalizzazione di mercato:
$192.08M
Reddito:
-
Utile/perdita netta:
$-71.17M
Rapporto P/E:
-1.929
EPS:
-1.55
Flusso di cassa netto:
$-70.97M
1 W Prestazione:
-1.32%
1M Prestazione:
+7.17%
6M Prestazione:
-32.05%
1 anno Prestazione:
-23.72%
Intervallo 1D:
$2.75
$3.03
Intervallo di 1 settimana:
$2.65
$3.28
Portata 52W:
$2.385
$7.795
Inozyme Pharma Inc Stock (INZY) Company Profile
Nome
Inozyme Pharma Inc
Settore
Industria
Telefono
857-330-4340
Indirizzo
321 SUMMER STREET, BOSTON
Confronta INZY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INZY
Inozyme Pharma Inc
|
2.99 | 192.08M | 0 | -71.17M | -70.97M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Inozyme Pharma Inc Stock (INZY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-12 | Iniziato | Raymond James | Outperform |
| 2024-09-12 | Iniziato | Stifel | Buy |
| 2024-08-13 | Ripresa | Jefferies | Buy |
| 2024-05-30 | Iniziato | Wells Fargo | Overweight |
| 2023-03-23 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-05-26 | Iniziato | Jefferies | Hold |
| 2022-02-07 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-29 | Iniziato | Needham | Buy |
| 2020-08-18 | Iniziato | BofA Securities | Buy |
| 2020-08-18 | Iniziato | Cowen | Outperform |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-18 | Iniziato | Wedbush | Outperform |
Mostra tutto
Inozyme Pharma Inc Borsa (INZY) Ultime notizie
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Recommendation of “Buy” by Analysts - Defense World
Inozyme Pharma (NASDAQ:INZY) Coverage Initiated at Raymond James - Defense World
Raymond James Begins Coverage on Inozyme Pharma (NASDAQ:INZY) - MarketBeat
Jefferies initiates Buy rating on Inozyme Pharma stock, highlights potential of INZ-701 - Investing.com
Affinity Asset Advisors, LLC Increases Stake in Inozyme Pharma I - GuruFocus.com
Inozyme Pharma stock hits 52-week low at $2.53 amid market challenges - Investing.com Canada
Eventide Asset Management LLC Purchases 198,216 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - MarketBeat
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Inozyme Pharma to Present at Piper Sandler Healthcare Conference | INZY Stock News - StockTitan
Inozyme Pharma stock hits 52-week low at $2.6 amid market challenges - Investing.com Canada
Analyzing Inozyme Pharma (NASDAQ:INZY) and Theratechnologies (NASDAQ:THTX) - Defense World
Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks - MSN
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet? - Simply Wall St
Inozyme Pharma stock hits 52-week low at $3.23 amid market shifts - Investing.com
Eventide Asset Management's Strategic Acquisition of Inozyme Pha - GuruFocus.com
Inozyme Pharma to Present at Upcoming Investor Conferences - GlobeNewswire
Inozyme Pharma CEO to Present at Stifel and Jefferies Healthcare Conferences | INZY Stock News - StockTitan
Inozyme Pharma’s (INZY) Buy Rating Reiterated at HC Wainwright - Defense World
Inozyme Pharma (NASDAQ:INZY) Given “Outperform” Rating at Wedbush - Defense World
FY2024 EPS Estimates for Inozyme Pharma Increased by Analyst - Defense World
Inozyme Pharma FY2024 EPS Forecast Raised by HC Wainwright - MarketBeat
FY2024 EPS Estimates for Inozyme Pharma Raised by Analyst - MarketBeat
Piper Sandler raises Inozyme Pharma target to $43 from $40 - Investing.com India
Inozyme Pharma's (INZY) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Inozyme Pharma's (INZY) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights - GlobeNewswire
Inozyme Pharma’s Q3 2024 Financial and Clinical Progress - TipRanks
Piper Sandler raises Inozyme Pharma target to $43 from $40 By Investing.com - Investing.com Canada
Inozyme Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Inozyme Pharma Reports Wider Q3 Loss, Advances Key Clinical Trials Despite $24.6M Loss | INZY Stock News - StockTitan
Analysts Set Inozyme Pharma, Inc. (NASDAQ:INZY) Price Target at $16.14 - MarketBeat
Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Average Rating of “Buy” from Analysts - Defense World
Needham & Company LLC Reiterates Buy Rating for Inozyme Pharma (NASDAQ:INZY) - MarketBeat
Inozyme reports positive trial results for kidney disease therapy - Investing.com India
Inozyme reports positive trial results for kidney disease therapy By Investing.com - Investing.com Canada
Inozyme Pharma Bullish on Treatment for End-Stage Kidney Disease - MarketWatch
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701 - GlobeNewswire
Inozyme Pharma Inc Azioni (INZY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):